MEMBRANE-BASED BLOOD RECONSTITUTION DEVICES

Information

  • Research Project
  • 2229692
  • ApplicationId
    2229692
  • Core Project Number
    R43HL052355
  • Full Project Number
    1R43HL052355-01
  • Serial Number
    52355
  • FOA Number
  • Sub Project Id
  • Project Start Date
    6/1/1994 - 32 years ago
  • Project End Date
    7/31/1995 - 31 years ago
  • Program Officer Name
  • Budget Start Date
    6/1/1994 - 32 years ago
  • Budget End Date
    7/31/1995 - 31 years ago
  • Fiscal Year
    1994
  • Support Year
    1
  • Suffix
  • Award Notice Date
    5/31/1994 - 32 years ago
Organizations

MEMBRANE-BASED BLOOD RECONSTITUTION DEVICES

DESCRIPTION: This is a Phase I SBIR request for support of a project to develop microporous hollow filters (MPHF) for use in separating glycerol from cryopreserved human blood cells following thawing. The Investigators propose that this type system would be practical, efficient and economic when compared to the current centrifugation practices employed to accomplish deglycerination at present. This is a project designed to develop similar methodology for the preparation of plasma by filtration for analysis. They cite preliminary data from their experience in which 3 ml of plasma can be isolated from 10 ml of whole blood by filtration through polysulfoam filters in a 3 minute period. They state that plasma obtained by that method is indistinguishable from that prepared by centrifugation when analyzed for hemolysis, glucose , BUN CO2 and total protein. They emphasizes that the system they are utilizing is a completely closed filtration system which should avoid contamination with microorganisms. They state that other filtration devices have been developed at SymBiotech which can extract drugs from plasma, serum and whole blood with about 90% efficiency using only 50 to 100 microliters of serum and less than 50 microliters of organic solvent. In Phase I of this application, they plan initially to determine the best MPHF material and dimensions for separating glycerine from the red blood cell fraction without inducing hemolysis. Subsequently, they plan to determine optimal blood flow rates through their system such that maximal glycerine can be removed from the blood cell suspension without inducing hemolysis. Then using this information, they will design and build a MPHF based blood reconstitution system consistent with the material and fluid mechanics determined in their initial studies. This device will subsequently be optimized to maximize efficiency and cost saving.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    HEM
  • Study Section Name
    Hematology Subcommittee 2
  • Organization Name
    SYMBIOTECH, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    WALLINGFORD
  • Organization State
    CT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    06492
  • Organization District
    UNITED STATES